All In Biotech

NDA 018612 · Haleon US Holdings

Nicorette

Nicotine Polacrilex · Buccal · Cholinergic Nicotinic Agonist

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jan 3, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Jan 13, 1984

Approved uses

4

Original approval plus efficacy supplements

Registered trials

873

97 Phase 3, 66 recruiting

FAERS reports

21,925

3,984 serious, 149 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 13, 2024.

Use reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 6, 2009 Supplement 52 · Efficacy Letter
  • Dec 23, 1998 Supplement 25 · Efficacy LetterReviewLabel
  • Feb 9, 1996 Supplement 22 · Efficacy Review
  • Jan 13, 1984 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • NICORETTE · NICOTINE POLACRILEX EQ 2MG BASE · GUM, CHEWING, BUCCAL · Over-the-counter
  • NICORETTE · NICOTINE POLACRILEX EQ 2MG BASE · GUM, CHEWING, BUCCAL · Over-the-counter
  • NICORETTE (MINT) · NICOTINE POLACRILEX EQ 2MG BASE · GUM, CHEWING, BUCCAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Nicotine Polacrilex" as an intervention, any sponsor and status, largest first.

All 873 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,651
  • nicotine dependence3,383
  • intentional drug misuse3,276
  • nausea1,926
  • drug administration error1,140
  • malaise1,015
  • oral discomfort715
  • dizziness703
  • dyspepsia662
  • wrong technique in product usage process656
  • product quality issue652
  • headache633

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004115
2005223
20061,148
20071,347
20081,063
20091,094
20101,044
20111,453
20121,517
20131,109
2014233
20151,570
20161,309
20171,308
20181,145
20191,038
2020921
20211,062
2022811
2023725
2024600
2025707
2026383

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 77 on PubMed

Sponsor: Haleon US Holdings · Also marketed as Nicorette (Mint)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.